LIFE LENGTH SL

Their core work

Life Length is a Madrid-based biotech SME that has used the H2020 SME Instrument to develop ONCOCHECK, a blood-based test intended to help clinicians monitor how cancer patients are responding to therapy and to inform prognosis. Their work combines laboratory assay development with the clinical and regulatory path needed to turn a biomarker test into a usable in vitro diagnostic. In H2020 they appear as a product-driven company: both of their grants funded their own pipeline rather than shared research. Their value to partners is a near-market oncology blood test and the commercialisation know-how behind it.

What they specialise in

How they've shifted over time

Between 2015 and 2018 their work stayed tightly on a single product line: ONCOCHECK, a blood test for cancer patients. The early SME-1 grant (EUR 50k in 2015) funded feasibility for therapy monitoring; the later SME-2 grant (EUR 3.1M in 2017-2018) scaled the concept into a prognostic and monitoring product. No new H2020 activity appears after 2018, so from EU-funding data alone the direction since then is not visible.

They appear to have committed fully to bringing the ONCOCHECK blood test to clinical use; partners useful to them would be oncology clinics, CROs for validation studies, or diagnostic distributors.

How they like to work

Life Length operated solo through the EU SME Instrument, coordinating both of their projects without named consortium partners in the CORDIS data. This is characteristic of a commercial SME developing a proprietary product rather than a research collaborator. Partners approaching them should expect a product-owner mindset: they drive their own roadmap and are most open to clinical validation partners, distribution channels, or oncology reference centres.

No co-participating organisations are recorded in their H2020 projects — both grants were solo SME Instrument awards. Activity is anchored in Madrid, Spain.

What sets them apart

Very few Spanish SMEs have pulled a single IVD product through both SME Phase 1 and Phase 2 with over EUR 3M of EC funding as sole coordinator, which signals a validated business case and a self-contained development capacity. Their niche — a blood-based assay for both prognosis and therapy monitoring in oncology — sits at the commercially attractive overlap of liquid biopsy and routine patient follow-up. For a partner, this means dealing with a product-focused company that already owns its IP and EU commercialisation pathway rather than a research lab.

Highlights from their portfolio

• ONCOCHECK (SME-2, 2017-2018)
  EUR 3.1M solo SME-2 grant to take a blood test for cancer prognosis and therapy monitoring toward market — a substantial single-beneficiary ticket in the health IVD space.
• ONCOCHECK (SME-1, 2015)
  The feasibility precursor that earned the company the larger Phase 2 follow-on, showing a clean SME-1 to SME-2 progression.